Page last updated: 2024-11-11

thymodepressin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

thymodepressin: a synthetic peptide, promoted take of transplanted hemopoietic precursor cells in the bone marrow of irradiated mice [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7275810
CHEMBL ID3137306
SCHEMBL ID733964
MeSH IDM0417847

Synonyms (28)

Synonym
thymodepressin
ccris 9010
270250-97-0
orilotimod [usan:inn]
unii-q66z43c5xm
orilotimod
186087-26-3
d-tryptophan, d-gamma-glutamyl-
d-gamma-glutamyl-d-tryptophan
q66z43c5xm ,
(2r)-2-amino-5-(((1r)-1-carboxy-2-(1h-indol-3-yl)ethyl)amino)-5-oxopentanoic acid
gamma-d-glu-d-trp
apo-805
timodepressin
apo805
CHEMBL3137306
orilotimod [inn]
d-tryptophan, d-.gamma.-glutamyl-
thymodepressin [who-dd]
d-.gamma.-glutamyl-d-tryptophan
orilotimod [usan]
SCHEMBL733964
D10651
orilotimod (usan/inn)
DTXSID10181511
CATMPQFFVNKDEY-DGCLKSJQSA-N
Q27287050
(2r)-2-amino-5-[[(1r)-1-carboxy-2-(1h-indol-3-yl)ethyl]amino]-5-oxopentanoic acid

Research Excerpts

Overview

Thymodepressin is a new synthetic hemoregulatory dipeptide.

ExcerptReferenceRelevance
"Thymodepressin is a new synthetic hemoregulatory dipeptide (gamma-D-Glu-D-Trp). "( [Use of thymodepressin for treating autoimmune cytopenia].
Deĭgin, VI; Orlova, NV; Pavlov, VV; Saenko, AS; Selivanova, EI; Smirnova, SG; Vinogradova, IuE; Zamulaeva, IA, 2002
)
2.19
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (66.67)29.6817
2010's1 (11.11)24.3611
2020's2 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]